Concepts (246)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Neoplasms | 8 | 2012 | 121 | 2.210 |
Why?
|
| Receptor, Parathyroid Hormone, Type 1 | 9 | 2009 | 11 | 2.030 |
Why?
|
| Parathyroid Hormone | 7 | 2009 | 44 | 1.700 |
Why?
|
| Breast Neoplasms | 9 | 2012 | 1216 | 1.320 |
Why?
|
| Wounds, Nonpenetrating | 8 | 2020 | 116 | 1.130 |
Why?
|
| Disease Models, Animal | 6 | 2012 | 2278 | 0.810 |
Why?
|
| Textiles | 1 | 2020 | 10 | 0.650 |
Why?
|
| Masks | 1 | 2020 | 20 | 0.640 |
Why?
|
| Exposure to Violence | 1 | 2019 | 5 | 0.610 |
Why?
|
| Intimate Partner Violence | 1 | 2019 | 25 | 0.590 |
Why?
|
| Receptors, Parathyroid Hormone | 3 | 2008 | 4 | 0.570 |
Why?
|
| Betacoronavirus | 1 | 2020 | 181 | 0.550 |
Why?
|
| Peptide Fragments | 5 | 2009 | 415 | 0.540 |
Why?
|
| Iodine | 1 | 2017 | 20 | 0.520 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 205 | 0.510 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 218 | 0.510 |
Why?
|
| Renal Insufficiency | 1 | 2017 | 67 | 0.500 |
Why?
|
| Wounds and Injuries | 1 | 2019 | 250 | 0.500 |
Why?
|
| Pandemics | 1 | 2020 | 669 | 0.450 |
Why?
|
| Contrast Media | 1 | 2017 | 429 | 0.430 |
Why?
|
| Bone and Bones | 3 | 2012 | 152 | 0.390 |
Why?
|
| COS Cells | 6 | 2009 | 180 | 0.390 |
Why?
|
| Disulfides | 2 | 2009 | 67 | 0.340 |
Why?
|
| Recombinant Proteins | 4 | 2007 | 709 | 0.330 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2011 | 55 | 0.330 |
Why?
|
| Benzophenones | 2 | 2008 | 20 | 0.330 |
Why?
|
| Mice, SCID | 5 | 2012 | 518 | 0.330 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2010 | 44 | 0.330 |
Why?
|
| Animals | 17 | 2012 | 21259 | 0.320 |
Why?
|
| Drug Discovery | 1 | 2011 | 95 | 0.320 |
Why?
|
| Protein Structure, Tertiary | 7 | 2008 | 676 | 0.310 |
Why?
|
| Parathyroid Hormone-Related Protein | 1 | 2009 | 9 | 0.310 |
Why?
|
| rho-Associated Kinases | 1 | 2009 | 18 | 0.310 |
Why?
|
| Cyclic AMP | 2 | 2009 | 144 | 0.300 |
Why?
|
| Tissue Engineering | 2 | 2007 | 148 | 0.300 |
Why?
|
| Cross-Linking Reagents | 2 | 2008 | 117 | 0.290 |
Why?
|
| Neoplasm Invasiveness | 1 | 2009 | 285 | 0.290 |
Why?
|
| Photoaffinity Labels | 1 | 2008 | 5 | 0.280 |
Why?
|
| Phenylalanine | 1 | 2008 | 25 | 0.270 |
Why?
|
| Models, Molecular | 7 | 2009 | 1159 | 0.270 |
Why?
|
| Humans | 33 | 2024 | 64818 | 0.270 |
Why?
|
| Protein Interaction Mapping | 1 | 2008 | 69 | 0.270 |
Why?
|
| Intracranial Hemorrhage, Traumatic | 2 | 2020 | 10 | 0.250 |
Why?
|
| Ligands | 5 | 2009 | 415 | 0.250 |
Why?
|
| Photochemistry | 1 | 2006 | 22 | 0.240 |
Why?
|
| Methionine | 1 | 2006 | 57 | 0.240 |
Why?
|
| Mice | 8 | 2012 | 11070 | 0.230 |
Why?
|
| Injury Severity Score | 5 | 2020 | 117 | 0.220 |
Why?
|
| Transplantation, Heterologous | 3 | 2012 | 240 | 0.220 |
Why?
|
| Spleen | 2 | 2020 | 474 | 0.220 |
Why?
|
| Female | 20 | 2024 | 33854 | 0.220 |
Why?
|
| In Vitro Techniques | 2 | 2020 | 491 | 0.210 |
Why?
|
| Mice, Inbred NOD | 3 | 2012 | 526 | 0.210 |
Why?
|
| Transfection | 5 | 2011 | 700 | 0.210 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2003 | 6 | 0.200 |
Why?
|
| Patient Transfer | 1 | 2024 | 92 | 0.200 |
Why?
|
| Cysteine | 3 | 2009 | 107 | 0.200 |
Why?
|
| Placebos | 1 | 2003 | 73 | 0.200 |
Why?
|
| Industry | 1 | 2003 | 59 | 0.200 |
Why?
|
| Ethics, Medical | 1 | 2003 | 40 | 0.190 |
Why?
|
| Signal Transduction | 2 | 2009 | 3137 | 0.190 |
Why?
|
| Osteoporosis | 1 | 2003 | 113 | 0.180 |
Why?
|
| Health Care Rationing | 1 | 2022 | 21 | 0.180 |
Why?
|
| Standard of Care | 1 | 2022 | 27 | 0.180 |
Why?
|
| Liver | 2 | 2020 | 868 | 0.180 |
Why?
|
| Anticoagulants | 2 | 2020 | 522 | 0.180 |
Why?
|
| Protein Conformation | 5 | 2009 | 790 | 0.180 |
Why?
|
| Cell Line, Tumor | 4 | 2011 | 1564 | 0.170 |
Why?
|
| Filtration | 1 | 2020 | 19 | 0.160 |
Why?
|
| Air Microbiology | 1 | 2020 | 11 | 0.160 |
Why?
|
| Retrospective Studies | 10 | 2022 | 6823 | 0.160 |
Why?
|
| Residence Characteristics | 1 | 2022 | 230 | 0.160 |
Why?
|
| Permeability | 1 | 2020 | 50 | 0.160 |
Why?
|
| Aerosols | 1 | 2020 | 46 | 0.160 |
Why?
|
| Trauma Centers | 7 | 2020 | 130 | 0.150 |
Why?
|
| Traumatology | 1 | 2019 | 14 | 0.150 |
Why?
|
| New England | 6 | 2020 | 269 | 0.150 |
Why?
|
| Community-Institutional Relations | 1 | 2019 | 42 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2003 | 799 | 0.150 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 542 | 0.150 |
Why?
|
| Stromal Cells | 2 | 2010 | 78 | 0.140 |
Why?
|
| Gene Expression Regulation | 1 | 2005 | 1629 | 0.140 |
Why?
|
| Cell Movement | 2 | 2012 | 478 | 0.140 |
Why?
|
| Bone Marrow Cells | 2 | 2010 | 237 | 0.140 |
Why?
|
| Water | 1 | 2020 | 313 | 0.140 |
Why?
|
| Particle Size | 1 | 2020 | 428 | 0.140 |
Why?
|
| Transforming Growth Factor beta | 2 | 2010 | 181 | 0.140 |
Why?
|
| Middle Aged | 12 | 2024 | 18163 | 0.140 |
Why?
|
| Neoplasm Metastasis | 2 | 2009 | 221 | 0.130 |
Why?
|
| Blotting, Western | 2 | 2009 | 609 | 0.130 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2009 | 297 | 0.130 |
Why?
|
| Kidney Function Tests | 1 | 2017 | 36 | 0.130 |
Why?
|
| Amino Acid Sequence | 4 | 2009 | 1589 | 0.130 |
Why?
|
| Alcoholism | 1 | 2020 | 327 | 0.130 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2008 | 251 | 0.130 |
Why?
|
| Flow Cytometry | 2 | 2009 | 661 | 0.130 |
Why?
|
| Program Evaluation | 1 | 2019 | 488 | 0.130 |
Why?
|
| Spinal Injuries | 1 | 2017 | 11 | 0.130 |
Why?
|
| Emigration and Immigration | 1 | 2017 | 28 | 0.130 |
Why?
|
| Biotechnology | 1 | 2017 | 37 | 0.130 |
Why?
|
| Societies, Medical | 1 | 2019 | 396 | 0.130 |
Why?
|
| Public Policy | 1 | 2017 | 38 | 0.120 |
Why?
|
| Gene Expression Profiling | 2 | 2010 | 790 | 0.120 |
Why?
|
| Hospitals | 1 | 2019 | 385 | 0.120 |
Why?
|
| Neoplasm Transplantation | 2 | 2007 | 168 | 0.120 |
Why?
|
| Molecular Sequence Data | 3 | 2009 | 1979 | 0.120 |
Why?
|
| Nanoparticles | 2 | 2020 | 544 | 0.120 |
Why?
|
| Cervical Vertebrae | 1 | 2017 | 119 | 0.120 |
Why?
|
| Cell Membrane | 2 | 2009 | 504 | 0.110 |
Why?
|
| Aged | 9 | 2022 | 14879 | 0.110 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 1160 | 0.100 |
Why?
|
| Male | 12 | 2024 | 30880 | 0.100 |
Why?
|
| Protein Engineering | 2 | 2011 | 85 | 0.090 |
Why?
|
| RNA, Messenger | 2 | 2009 | 1576 | 0.090 |
Why?
|
| Adolescent | 4 | 2017 | 6280 | 0.090 |
Why?
|
| Risk Factors | 4 | 2017 | 5401 | 0.090 |
Why?
|
| Bone Transplantation | 1 | 2012 | 31 | 0.090 |
Why?
|
| Arthropod Proteins | 1 | 2011 | 8 | 0.090 |
Why?
|
| Melanoma, Experimental | 1 | 2011 | 42 | 0.090 |
Why?
|
| Receptors, Interleukin-17 | 1 | 2010 | 2 | 0.080 |
Why?
|
| Kidney | 1 | 2013 | 450 | 0.080 |
Why?
|
| Protein Structure, Secondary | 2 | 2009 | 260 | 0.080 |
Why?
|
| Ticlopidine | 1 | 2011 | 47 | 0.080 |
Why?
|
| Craniocerebral Trauma | 1 | 2011 | 53 | 0.080 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 2 | 2008 | 84 | 0.080 |
Why?
|
| Foreign-Body Migration | 1 | 2010 | 24 | 0.080 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2010 | 30 | 0.080 |
Why?
|
| Cell Communication | 1 | 2010 | 133 | 0.080 |
Why?
|
| Interleukin-17 | 1 | 2010 | 99 | 0.080 |
Why?
|
| United States | 2 | 2019 | 8058 | 0.080 |
Why?
|
| Rib Fractures | 1 | 2010 | 22 | 0.080 |
Why?
|
| Hydrocephalus | 1 | 2010 | 41 | 0.080 |
Why?
|
| Herniorrhaphy | 1 | 2010 | 71 | 0.080 |
Why?
|
| Warfarin | 1 | 2011 | 124 | 0.080 |
Why?
|
| Adult | 7 | 2017 | 17271 | 0.080 |
Why?
|
| Bone Resorption | 1 | 2009 | 46 | 0.070 |
Why?
|
| Breast | 1 | 2011 | 190 | 0.070 |
Why?
|
| Gene Transfer Techniques | 1 | 2011 | 324 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2009 | 112 | 0.070 |
Why?
|
| Abdominal Injuries | 1 | 2009 | 31 | 0.070 |
Why?
|
| Mutant Proteins | 1 | 2009 | 105 | 0.070 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2011 | 233 | 0.070 |
Why?
|
| Factor Xa | 1 | 2008 | 5 | 0.070 |
Why?
|
| Bombyx | 1 | 2007 | 10 | 0.070 |
Why?
|
| Enzyme Inhibitors | 1 | 2009 | 367 | 0.070 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2007 | 49 | 0.070 |
Why?
|
| Binding Sites | 2 | 2008 | 920 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 2237 | 0.070 |
Why?
|
| Models, Chemical | 1 | 2008 | 134 | 0.070 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2007 | 64 | 0.070 |
Why?
|
| Baculoviridae | 1 | 2007 | 24 | 0.060 |
Why?
|
| Insecta | 1 | 2007 | 36 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2020 | 1653 | 0.060 |
Why?
|
| DNA Primers | 1 | 2007 | 300 | 0.060 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2007 | 364 | 0.060 |
Why?
|
| Gene Expression | 1 | 2009 | 852 | 0.060 |
Why?
|
| Sodium Chloride | 1 | 2006 | 65 | 0.060 |
Why?
|
| Protein Transport | 1 | 2007 | 404 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 642 | 0.060 |
Why?
|
| Bioreactors | 1 | 2005 | 36 | 0.060 |
Why?
|
| Phosphorylcholine | 1 | 2006 | 45 | 0.060 |
Why?
|
| Computer Simulation | 1 | 2008 | 483 | 0.060 |
Why?
|
| Amino Acid Substitution | 1 | 2006 | 237 | 0.060 |
Why?
|
| Femur | 1 | 2005 | 55 | 0.060 |
Why?
|
| Cloning, Molecular | 1 | 2005 | 384 | 0.060 |
Why?
|
| Escherichia coli | 2 | 2007 | 706 | 0.060 |
Why?
|
| Base Sequence | 1 | 2007 | 1328 | 0.050 |
Why?
|
| Cells, Cultured | 2 | 2006 | 2183 | 0.050 |
Why?
|
| Tertiary Care Centers | 1 | 2024 | 110 | 0.050 |
Why?
|
| Genetic Therapy | 1 | 2011 | 832 | 0.050 |
Why?
|
| Cell Survival | 1 | 2005 | 582 | 0.050 |
Why?
|
| Protein Binding | 1 | 2008 | 1638 | 0.050 |
Why?
|
| RNA, Small Interfering | 1 | 2009 | 980 | 0.050 |
Why?
|
| MicroRNAs | 1 | 2009 | 709 | 0.050 |
Why?
|
| Receptors, Vitronectin | 1 | 2002 | 4 | 0.050 |
Why?
|
| Prognosis | 1 | 2007 | 1774 | 0.050 |
Why?
|
| Trauma Severity Indices | 2 | 2013 | 33 | 0.050 |
Why?
|
| Organ Dysfunction Scores | 1 | 2022 | 23 | 0.050 |
Why?
|
| Obesity | 1 | 2010 | 1264 | 0.050 |
Why?
|
| Health Priorities | 1 | 2022 | 29 | 0.050 |
Why?
|
| Models, Biological | 1 | 2007 | 1192 | 0.040 |
Why?
|
| Oligopeptides | 1 | 2002 | 134 | 0.040 |
Why?
|
| Cell Line | 1 | 2005 | 2019 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2005 | 1034 | 0.040 |
Why?
|
| Boston | 1 | 2022 | 257 | 0.040 |
Why?
|
| Vulnerable Populations | 1 | 2022 | 94 | 0.040 |
Why?
|
| Platelet Count | 1 | 2020 | 26 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2024 | 518 | 0.040 |
Why?
|
| Hospitalization | 2 | 2022 | 1380 | 0.040 |
Why?
|
| Mutation | 1 | 2008 | 2655 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2003 | 1689 | 0.040 |
Why?
|
| Critical Care | 1 | 2022 | 400 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2013 | 5583 | 0.030 |
Why?
|
| Length of Stay | 2 | 2013 | 823 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 741 | 0.030 |
Why?
|
| Population Dynamics | 1 | 2017 | 21 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2022 | 407 | 0.030 |
Why?
|
| Treatment Outcome | 3 | 2013 | 5773 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2022 | 1555 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2003 | 2091 | 0.030 |
Why?
|
| Disease Progression | 1 | 2020 | 1214 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2010 | 2607 | 0.030 |
Why?
|
| Multiple Trauma | 1 | 2013 | 29 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 2013 | 75 | 0.020 |
Why?
|
| Silk | 1 | 2011 | 8 | 0.020 |
Why?
|
| Young Adult | 2 | 2012 | 4782 | 0.020 |
Why?
|
| Glasgow Coma Scale | 1 | 2011 | 48 | 0.020 |
Why?
|
| Peritoneal Cavity | 1 | 2010 | 30 | 0.020 |
Why?
|
| Plasmids | 1 | 2011 | 293 | 0.020 |
Why?
|
| Hernia | 1 | 2010 | 14 | 0.020 |
Why?
|
| Splenectomy | 1 | 2010 | 39 | 0.020 |
Why?
|
| Surgical Mesh | 1 | 2010 | 60 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2010 | 206 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2017 | 3300 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2013 | 873 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 213 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2009 | 414 | 0.020 |
Why?
|
| Peptides | 2 | 2002 | 587 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2009 | 104 | 0.020 |
Why?
|
| Survival Rate | 1 | 2010 | 843 | 0.020 |
Why?
|
| Incidence | 1 | 2011 | 1411 | 0.020 |
Why?
|
| Nitrogen Isotopes | 1 | 2006 | 10 | 0.010 |
Why?
|
| Buffers | 1 | 2006 | 22 | 0.010 |
Why?
|
| Glutathione Transferase | 1 | 2006 | 38 | 0.010 |
Why?
|
| Age Factors | 1 | 2010 | 1579 | 0.010 |
Why?
|
| Time Factors | 1 | 2013 | 3750 | 0.010 |
Why?
|
| Solutions | 1 | 2006 | 63 | 0.010 |
Why?
|
| Micelles | 1 | 2006 | 83 | 0.010 |
Why?
|
| Massachusetts | 1 | 2011 | 2140 | 0.010 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2006 | 281 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2006 | 500 | 0.010 |
Why?
|
| beta-Arrestin 2 | 1 | 2002 | 2 | 0.010 |
Why?
|
| beta-Arrestins | 1 | 2002 | 5 | 0.010 |
Why?
|
| Disintegrins | 1 | 2002 | 4 | 0.010 |
Why?
|
| Arrestins | 1 | 2002 | 10 | 0.010 |
Why?
|
| Peptides, Cyclic | 1 | 2002 | 23 | 0.010 |
Why?
|
| Iodine Radioisotopes | 1 | 2002 | 59 | 0.010 |
Why?
|
| Second Messenger Systems | 1 | 2002 | 27 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 2002 | 96 | 0.010 |
Why?
|
| Protein Subunits | 1 | 2002 | 169 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2009 | 1314 | 0.010 |
Why?
|
| Endocytosis | 1 | 2002 | 152 | 0.010 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2002 | 156 | 0.010 |
Why?
|
| Crystallography, X-Ray | 1 | 2002 | 419 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2002 | 401 | 0.010 |
Why?
|
| Kinetics | 1 | 2002 | 757 | 0.010 |
Why?
|